<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00530140</url>
  </required_header>
  <id_info>
    <org_study_id>CUN-90-2006</org_study_id>
    <nct_id>NCT00530140</nct_id>
  </id_info>
  <brief_title>Idiotypic Vaccination for Follicular Lymphoma Patients</brief_title>
  <acronym>FLIDVAX2006</acronym>
  <official_title>Idiotypic Vaccination for Poor-prognosis Follicular Lymphoma Patients in First Relapse</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Clinica Universidad de Navarra, Universidad de Navarra</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Navarrra Hospital (Clinica Universitaria)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Center for Applied Medical Research (Centro de Investigación Médica Aplicada)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Clinica Universidad de Navarra, Universidad de Navarra</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Poor prognosis follicular lymphoma patients have an estimated median overall survival of 5-6
      years. The proposed trial offers life-time idiotypic vaccination to all such patients in
      first relapse/progression who will achieve second (first, in the case of patients who have
      never achieved complete response following standard first-line treatment) complete response
      through autologous stem cell transplant prior to vaccination start. The ultimate goal is a
      cure, defined as a vaccine-maintained complete response lasting both at least 10 years and at
      least twice as long as each patient's first complete response.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Idiotypic vaccination has already proved capable (in responding patients) of: biological
      efficacy, that is the capacity of inducing an idiotype- and tumor-specific immune response
      (Kwak LW et al. NEJM 1992); clinical efficacy, that is the capacity of inducing specific
      immune responses able to kill in vivo follicular lymphoma cells that had survived pre-vaccine
      chemotherapy (Bendandi M et al. Nature Med 1999): clinical benefit, that is the capacity of
      prolonging survival of responding patients (Inoges et al. JNCI 2006). Now, we want to test
      whether it is also capable of contributing to the ultimate goal of preventing relapse
      indefinitely in responding patients.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2007</start_date>
  <completion_date type="Anticipated">September 2022</completion_date>
  <primary_completion_date type="Anticipated">September 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of patients who both never relapse and have a second complete response longer than their first response (cured)</measure>
    <time_frame>15 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients who successfully maintain a measurable, specific immune response throughout the active vaccination time frame</measure>
    <time_frame>15 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Follicular Lymphoma</condition>
  <condition>First Relapse/Progression</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All patients will receive the same vaccination schedule/formulation</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Follicular lymphoma, patient-specific, soluble protein idiotype vaccine</intervention_name>
    <description>0.5 mg of idiotype conjugated to 0.5 mg of KLH + 125 mcg of GM-CSF 5 monthly vaccinations followed by 3 bi-monthly vaccinations, followed by one boost every three months until either relapse or death from cause unrelated to lymphoma</description>
    <arm_group_label>A</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria: at least one of the following:

          -  FLIPI score 3 thru 5 at diagnosis and/or at relapse

          -  First complete response shorter than 3 years, if no maintenance (Interferon,
             Rituximab, etc) treatment was administered, or than 5 years if maintenance treatment
             was administered

          -  No treatment has been able to induce complete response until autologous stem cell
             transplant

          -  Poor-prognosis genomic profiling

        Exclusion Criteria: any of the following:

          -  Unavailability of a harvestable lymph node of at least cm 2x2x2

          -  Life expectancy &lt; 1 year

          -  Abnormal heart or liver or kidney function

          -  ECOG Performance Status &gt; 2

          -  Failure to sign informed consent before enrollment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>MAURIZIO BENDANDI, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Navarra</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>MAURIZIO BENDANDI, MD, PhD</last_name>
    <phone>+34606002087</phone>
    <email>mbendandi@unav.es</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>SUSANA INOGES, MD, PhD</last_name>
    <phone>+34685972257</phone>
    <email>sinoges@unav.es</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Navarra Hospital</name>
      <address>
        <city>Pamplona</city>
        <state>Navarra</state>
        <zip>31008</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>MAURIZIO BENDANDI, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <reference>
    <citation>Inogès S, Rodrìguez-Calvillo M, Zabalegui N, Lòpez-Dìaz de Cerio A, Villanueva H, Soria E, Suárez L, Rodríguez-Caballero A, Pastor F, García-Muñóz R, Panizo C, Pèrez-Calvo J, Melero I, Rocha E, Orfao A, Bendandi M; Grupo Español de Linfomas/Trasplante Autologo de Medula Oseo study group; Programa para el Estudio y Tratamiento de Hemopatias Malignas study group. Clinical benefit associated with idiotypic vaccination in patients with follicular lymphoma. J Natl Cancer Inst. 2006 Sep 20;98(18):1292-301.</citation>
    <PMID>16985248</PMID>
  </reference>
  <verification_date>October 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 12, 2007</study_first_submitted>
  <study_first_submitted_qc>September 13, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 17, 2007</study_first_posted>
  <last_update_submitted>October 5, 2011</last_update_submitted>
  <last_update_submitted_qc>October 5, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 6, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Follicular Lymphoma</keyword>
  <keyword>Idiotype vaccine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Follicular</mesh_term>
    <mesh_term>Recurrence</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
    <mesh_term>Immunoglobulin Idiotypes</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

